T h e introduction of microarray technology to the scientific and medical communities has dramatically changed the way in which we now address basic biomedical questions. Expression profiling using microarrays facilitates an experimental approach where alterations in the transcript level of entire transcriptomes can be simultaneously assayed in response to defined stimuli. We have used microarray analysis to identify downstream transcriptional targets of the BRCAl (Beast Cancer 1 ) tumour-suppressor gene as a means of defining its function. BRCAl has been implicated in the predisposition to early onset breast and ovarian cancer and while its exact function remains to be defined, roles in DNA repair, cell-cycle control and transcriptional regulation have been implied. In the current study we have generated cell lines with tetracycline-regulated, inducible expression of BRCAl as a tool to identify genes, which might represent important effectors of BRCAl function.
Oligonucleotide array-based expression profiling identified a number of genes that were upregulated at various times following inducible expression of BRCAl including the DNA damage-responsive gene GADD45 (Growth Arrest after D N A
Introduction
Microarray technology is currently being used in a high-throughput approach to study gene expression and sequence variation on a genomic scale. This report is primarily focused on the use of microarray technology in RNA expression studies as a means of identifying signalling pathways regulated by key genes implicated in tumorigenesis. T h e term expression profiling, however, encompasses a wide variety of different experimental strategies that use alterations in transcriptional profile as a means to explain the molecular basis of how specified experimental models respond to particular stimuli or changes in homeostasis, whether they are induced or occur naturally.
T h e objective of the current study is to use oligonucleotide array-based expression profiling to identify downstream targets of the BRCAl tumour suppressor gene that may represent important effectors of BRCAl function.
BRCA I tumour suppressor gene
BRCAl encodes a tumour suppressor gene that is mutated in the germline of women with a genetic predisposition to breast and ovarian cancer [ 11. Germline mutations of BRCAl are found in half of breast-ovarian cancer pedigrees and in approx. 1Oo0 of women with early onset of breast cancer, irrespective of family history [2]. Somatic inactivation of BRCAl is rare in sporadic breast cancers [3] ; however, mutations have been observed in approx. 1Oo0 of sporadic ovarian cancers, suggesting potentially distinct genetic mechanisms for these two diseases [4] . It has also been reported that reduced BRCAl protein expression is observed in the majority of sporadic breast cancers, indicating that an epigenetic mechanism may also play a role in regulating BRCAl expression [5] . Most mutations that have been identified to date result in premature truncation of the BRCAl protein and, consistent with BRCAl's role as a tumour suppressor gene, tumours typically exhibit loss of heterozygosity of the remaining wild-type allele.
BRCAl encodes a unique 1863 amino acid phosphoprotein that is predominantly localized to the nucleus. An N-terminal ring finger motif mediates a physical interaction with BARD1 (BRCA1 Associated Ring Domain l ) , another ring finger protein that is implicated in RNA processing [6] . Sequence analyses has identified a previously undescribed C-terminal BRCT (BRRCAl C-Terminal) motif, postulated to play a role in cell-cycle checkpoint control in response to DNA damage [7] . Consistent with these observations, BRCAl becomes hyperphosphorylated in response to various DNA damaging agents including y-irradiation, an effect that is mediated in part by the A T M (ataxia telangiectasia mutated) [8] and chk2 kinases [9] .
BRCAl has also been shown to co-localize with RAD5 1, the mammalian homologue of bacterial recA, which is involved in homologous recombination and the repair of double strand breaks in DNA that occur after exposure to ionizing radiation [lo] . BRCAl has also been implicated in cell-cycle checkpoint control by becoming hyperphosphorylated during late GI-phase and Sphase and transiently dephosphorylated early after M-phase [ 113. Overexpression of BRCAl has been shown to induce a GI arrest in human colon cancer cells [ 121 and genetic instability has been observed in BRCAl exon 11 isoform-deficient cells resulting from a defective G,M checkpoint and centrosome amplification [13] .
A specific role has been postulated for BRCAl in transcriptional regulation. T h e C-terminal domain of BRCAl is highly acidic, a feature of many transcription factors, and has also been shown to mediate transcriptional activation when fused to a heterologous DNA binding domain [14, 15] . Furthermore, BRCAl co-purifies with RNA polymerase I I holoenzyme complex through an association with RNA helicase A [16, 17] , suggesting that BRCAl is a component of the core transcriptional machinery. A number of other reports have demonstrated that BRCAl associates with a range of different sequence specific transcription factors including p53 [18] , c-Myc [19] , activating transcription factor 1 (ATF-1) [20] and STAT1 (signal transduction and activator of transcription) [2 13, and modulates their activity. These findings suggest that BRCAl functions as either a coactivator or co-repressor of transcription, an effect which may involve its ability to recruit both the basal transcription machinery and a number of factors implicated in chromatin remodelling including components of the histone deacetylase complex (HDAC-1 and -2) [22] and the SWI/SNF-related chromatin remodelling complex [23] . BRCAl has, therefore, been implicated in at least three functional pathways: (i) mediating the cellular response to DNA damage, (ii) as a cellcycle checkpoint protein and (iii) in the regulation of transcription. T h e physiological significance of these properties and their implications for the function of BRCAl as a tumour suppressor gene remain to be defined.
Oligonucleotide arrays
Oligonucleotide arrays, which were pioneered by Affymetrix (http://www.affymetrix.com/), are generated using a combination of oligonucleotide synthesis and photolithography to synthesize specific oligonucleotides in a predetermined spatial orientation on a solid surface such as glass or silicon [24, 25] . This is achieved by attaching synthetic linker molecules that have been modified with a photochemically-removable protecting group to a solid support, such as glass or silicon. A photolithographic mask is then applied, through which UV-light is passed, thereby generating localized areas of photo-deprotection, to which protected deoxyribonucleotides are attached in a chemical coupling reaction. Each photolithographic mask generates different areas of photodeprotection on the solid substrate and, using a combination of these masks with an intervening chemical coupling step, the desired probes are synthesized at the sites specified in the original design [26] . For expression profiling-based approaches, fluorescently labelled probes are generated from test and reference samples to be compared. For Affymetrix-based oligonucleotide arrays, fluorescent probes are generated by reverse transcribing total RNA using an oligo-dT primer containing a T 7 polymerase site. Amplification and labelling of the cDNA probe is achieved by carrying out an in aitro transcription reaction in the presence of a biotinylated deoxyribonucleotides, resulting in the linear amplification of the cDNA population (approx. 3C100 fold). T h e biotin-labelled cRNA probe generated from test and reference samples is then hybridized to separate oligonucleotide arrays followed by binding to a streptavidin-conjugated fluorescent marker. Detection of bound probe is achieved after laser excitation of the fluorescent marker and scanning of the resultant emission spectra using a scanning confocal laser microscope. T h e differential fluorescent signal is then represented as alterations in transcriptional profile between the two compared samples.
Identification of BRCA I target genes
Comparing transcriptional profiles as a means of defining downstream signalling pathways has previously been validated by various researchers using alternative techniques, such as differential display [27] , and by serial analysis of gene expression [28] . T h e advent of microarray technology has dramatically simplified the experimental design required in this approach allowing the simultaneous identification of all potential targets. T h e major drawback, at present, to using arrays in this manner is that it is entirely dependent on the amount of information available on the genome under investigation. However, the rapid completion of the human genome sequencing project and the speed at which various other genomes have been or are in the process of being sequenced will, in due course, make this issue redundant. In order to identify downstream targets of BRCAl, we used the 'tetracycline off' (Tet-off) inducible expression system [29] to generate cell lines with highly regulated inducible expression of BRCAl (Figure 1 ). T h e use of this type of expression system facilitates the alteration of a single parameter within the experimental design namely the induction of BRCAl. T h e advantage of this approach is that the genetic background of the two populations to be compared are essentially identical, the only exception being the induction of BRCAl in one population. Therefore, the ques- tion being asked is clearly defined, thereby dramatically reducing the expected output in terms of targets from the array experiment. We established inducible, tetracycline-regulated expression of BRCAl in two cell types: UBR60-bc12 cells derived from the U 2 0 S osteosarcoma cell line and MBR62-bc12 cells derived from the MDA435 breast cancer cell line. Western blot analysis demonstrated tightly regulated induction of BRCAl expression (Figure 1 ). Inducible expression levels were shown to increase by approx. 5-fold above endogenous BRCAl levels in these cell lines following tetracycline withdrawal. This is well within the physiological levels observed for this protein in mouse models, where BRCAl expression has been shown to increase 10-fold during pregnancy, a level that is maintained through postlactional involution [30] . Biotinylated cRNA probes derived from cells in which exogenous BRCAl was switched off (+tetracycline) and switched on (-tetracycline) were hybridized to high-density oligonucleotide arrays representing 6800 known transcripts and expressed sequence tags (ESTs) [24, 25] . Twentythree genes and ESTs, identified as having increased expression following BRCAl induction by array hybridization, were confirmed by Northern blot analysis. T h e gene exhibiting the greatest degree of differential signal intensity was the stress-and DNA damage-inducible gene, GADD45 [31] (Figure 2 ).
Functional relevance of identified targets
T h e major criticism that can be levelled at this type of approach is that the expression levels achieved in these artificial expression systems are not physiologically relevant. While this is undeniably true, it is up to the investigator to devise additional experimental checks to confirm that genes identified in this manner represent physiologically relevant targets. In the current study we confirmed our findings by Northern blot analysis and observed increased expression of GADD45 as early as 6 h after inducible expression of BRCAl in both the oestosarcoma and breast cancerderived cell lines, in agreement the results observed by array hybridization (Figure 3A and 3B) . T h e level of GADD45 induction by BRCAl was shown to be comparable with that induced by other well described stimuli, including overexpression of wild-type p53, IR and UV [31] . At least two distinct pathways leading to the induction of GADD45 have been described. IR triggers the ATM-and p53-dependent induction of GADD45, which is mediated through a p53-responsive element within intron 3 [32] . A second, p53-independent, pathway has also been described in response to methyl methanesulphonate (MMS), U V irradiation and serum starvation [33] . We demonstrated that MMS-induced activation of GADD45 is abrogated in the BRCAl mutant cell line HCC1937, which suggests that MMSinduced expression of GADD45 may be mediated in part by BRCAl. Consistent with this observation, we demonstrated that GADD45 induction by BRCAl is p53-independent [31] .
A number of additional studies have supported this finding, thereby confirming that GADD45 represents a functionally important transcriptional target for BRCAl. A BRCAl responsive sequence has been identified in the Fluorescent image generated using the Affymetrix human cancer G I I0 array containing approx. I700 genes that have been implicated in cancer
Individual arrays were hybndized with biotinylated cRNA probes that were generated from cells in which exogenous BRCA I was induced or repressed. The image shows GADD45, which was identified as being a transcnptional target of BRCA I (pnnted with permission from AFfymetnx).
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proximal GADD45 promoter and has been shown to contain a potential C/EBP binding site [34] . A potential model, through which BRCAl regulates expression of GADD45, has come from a number of related studies. It has previously been demonstrated that BRCAl can repress c-Myc-mediated transactivation [35] . In addition, it has been reported that c-Myc can repress GADD45 expression through the C/EBP element within the GADD45 promoter [36] . It is postulated, therefore, that BRCAl -mediated induction of GADD45 may be achieved through the ability of BRCAl to relieve transcriptional repression induced b y c-Myc at the GADD45 promoter. Speculation as to the functional significance of BRCAl -mediated induction of GADD45 has come from a number of additional studies. GADD45 has been demonstrated to bind and activate the mitogen-activated protein kinase M T K l / M E K 4 , an upstream regulator of the c-Jun N-terminal kinase/stress-activated protein kinase pathway [37] . Consistent with this, we observed that forced expression of BRCAl induced apoptosis, which was dependent on c-Jun N-terminal kinase/stress-activated protein kinase pathway activation [3 13, therefore suggesting a possible role for GADD45 in mediating BRCAlinduced cell death. Both BRCAl and GADD45 have also been implicated in the regulation of the G,/M checkpoint. GADD45 has been shown to induce G,/M cell-cycle arrest through its ability to bind cdc2 and disrupt the cyclin B1-cdc2 complex, which is essential for progression into mitosis [38] . A number of studies support a role for BRCAl in mediating the G,/M checkpoint in human cells. A dominant negative BRCAl construct encoding the C-terminus was shown to abrogate GJM arrest in response to the spindle poison, colchicine [39] . Moreover, BRCAl has been shown to localize to centromeres via a physical interaction with y-tubulin, thereby suggesting that BRCAl plays a direct role in the accurate segregation of duplicated chromosomes during mitosis [40] . Additional studies in mice have confirmed these findings by revealing genetic instability and centrosome amplification in BRCAl exon 11 isoform-deficient cells, which may result from a defective G,/M checkpoint I would like to acknowledge Dr Daniel Haber in whose lab the majority of the BRCAl work was camed out. Jamie Bean who contributed significantly to this work and Jonathon Oliner from Afimetrix who camed out the oligonucleotide array experiments.
